Order Article Reprints

Maglio A, Vitale C, Pellegrino S, Calabrese C, D’Amato M, Molino A, Pelaia C, Triggiani M, Pelaia G, Stellato C, et al. Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines. 2021; 9(11):1550. https://doi.org/10.3390/biomedicines9111550

Maglio, Angelantonio, Carolina Vitale, Simona Pellegrino, Cecilia Calabrese, Maria D’Amato, Antonio Molino, Corrado Pelaia, Massimo Triggiani, Girolamo Pelaia, Cristiana Stellato, and et al. 2021. "Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma" Biomedicines 9, no. 11: 1550. https://doi.org/10.3390/biomedicines9111550

Maglio, A., Vitale, C., Pellegrino, S., Calabrese, C., D’Amato, M., Molino, A., Pelaia, C., Triggiani, M., Pelaia, G., Stellato, C., & Vatrella, A. (2021). Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines, 9(11), 1550. https://doi.org/10.3390/biomedicines9111550